A Better Way to Predict – and Prevent – Heart Disease? New Test Shows Promise
For years, millions of Americans have relied on a standard blood test to measure “poor” cholesterol (LDL) as a key indicator of heart health. But a groundbreaking new study from Northwestern Medicine suggests this widely-used test may not be the most effective way to guide treatment and prevent heart attacks and strokes.
The ApoB Advantage: Counting Harmful Particles
The research, published in JAMA, highlights the potential of another blood test, apolipoprotein B (apoB), to more accurately assess cardiovascular risk. Unlike LDL, which measures the amount of cholesterol carried in the blood, apoB counts the total number of harmful particles – a more comprehensive measure of risk.
“Research strongly shows that apolipoprotein B is better at identifying who is at risk, because it counts the total number of harmful particles in the blood,” explains study lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine.
Cost-Effectiveness: A Key Factor
Previous concerns surrounding the wider adoption of apoB testing centered on cost and convenience. The test typically requires an additional blood draw beyond the standard cholesterol panel. However, this new study is the first to demonstrate that using apoB to guide cholesterol-lowering treatment is not only more effective but also cost-effective for U.S. Healthcare payers.
Researchers used a large computer simulation model representing 250,000 U.S. Adults eligible for statins. Comparing strategies guided by LDL, non-HDL cholesterol, and apoB, they found that apoB-guided care improved population health, saved more lives, and did so in a financially responsible manner.
New Guidelines and Expanding Treatment Options
The timing of this research is particularly relevant. The American Heart Association and other medical associations recently issued updated guidelines recommending earlier initiation of cholesterol-lowering therapy for many patients. With a growing arsenal of medications available – including statins and ezetimibe – accurately identifying those who would benefit most from intensive treatment is crucial.
This means a shift in focus towards more precise risk assessment is underway, and apoB testing could play a central role.
Future Trends: Personalized Cardiovascular Care
The move towards apoB testing signals a broader trend in cardiovascular care: a move towards personalized medicine. Rather than relying on broad guidelines, clinicians are increasingly seeking more individualized assessments of risk to tailor treatment plans.
People can anticipate further advancements in diagnostic tools and therapies. The integration of genetic testing, advanced imaging techniques like CT scans [ Northwestern University], and continuous glucose monitoring could provide a more holistic view of cardiovascular health.
FAQ
Q: What is apolipoprotein B (apoB)?
A: ApoB counts the total number of harmful particles in the blood that can contribute to plaque buildup in arteries.
Q: Is apoB testing widely available?
A: While apoB testing is available, it is not yet routinely used in standard cholesterol panels.
Q: Is apoB testing expensive?
A: The study suggests that the benefits of apoB-guided treatment outweigh the additional cost of the test.
Q: What should I do if I’m concerned about my heart health?
A: Talk to your doctor about your risk factors and whether apoB testing might be appropriate for you.
Pro Tip: Don’t wait for your doctor to bring up advanced testing. Be proactive and ask about apoB if you have concerns about your cardiovascular risk.
Want to learn more about heart health and preventative care? Explore our other articles or subscribe to our newsletter for the latest updates.
